A magnesium citrate glycinate co-salt has a formula of Mg.sub.2C.sub.8H.sub.9NO.sub.9—XH.sub.2O and a suggested structure of:

##STR00001##

The magnesium citrate glycinate co-salt has an apparent density of 1740 kg/m.sup.3 and is compressible in a range of compression pressures from approximately 50 MPa to approximately 150 MPa. The magnesium citrate glycinate co-salt is formed by combining citric acid and glycine in a 1:1 molar ratio to form an aqueous reaction mixture and neutralizing the aqueous reaction mixture with a magnesium source having a magnesium:ligand ratio of 1:1.

A magnesium citrate glycinate co-salt has a formula of Mg.sub.2C.sub.8H.sub.9NO.sub.9—XH.sub.2O and a suggested structure of:

##STR00001##

The magnesium citrate glycinate co-salt has an apparent density of 1740 kg/m.sup.3 and is compressible in a range of compression pressures from approximately 50 MPa to approximately 150 MPa. The magnesium citrate glycinate co-salt is formed by combining citric acid and glycine in a 1:1 molar ratio to form an aqueous reaction mixture and neutralizing the aqueous reaction mixture with a magnesium source having a magnesium:ligand ratio of 1:1.

The invention describes hydrosoluble iron (III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids. The iron (III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment of iron deficiency anemia in humans or animals and pharmaceutical or food compositions containing them.

The invention describes hydrosoluble iron (III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids. The iron (III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment of iron deficiency anemia in humans or animals and pharmaceutical or food compositions containing them.

It is provided a compound of formula (I); wherein R.sup.5 is selected from the group consisting of H, OM, COOM, NH.sub.2, SO.sub.3M, (C.sub.1-C.sub.4)alkyl, and halogen; and A is a radical having at least 3 C atoms selected from the group consisting of: i) a radical of formula (i) wherein R.sup.7 is selected from the group consisting of OM, and COOM, and n is 0, 1 or 2; and ii) a radical of formula (ii) or of formula (iii) wherein R.sup.8 is selected from the group consisting of H, (C.sub.1-C.sub.4)alkyl; and wherein M is independently selected from the group consisting of H, an alkaly metal, and NH.sub.4.sup.+. It is also provided a process for the preparation thereof, a composition comprising it, and its use for correcting deficiencies of metals in plants. ##STR00001##

It is provided a compound of formula (I); wherein R.sup.5 is selected from the group consisting of H, OM, COOM, NH.sub.2, SO.sub.3M, (C.sub.1-C.sub.4)alkyl, and halogen; and A is a radical having at least 3 C atoms selected from the group consisting of: i) a radical of formula (i) wherein R.sup.7 is selected from the group consisting of OM, and COOM, and n is 0, 1 or 2; and ii) a radical of formula (ii) or of formula (iii) wherein R.sup.8 is selected from the group consisting of H, (C.sub.1-C.sub.4)alkyl; and wherein M is independently selected from the group consisting of H, an alkaly metal, and NH.sub.4.sup.+. It is also provided a process for the preparation thereof, a composition comprising it, and its use for correcting deficiencies of metals in plants. ##STR00001##

The invention describes hydrosoluble iron (III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids. The iron (III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment of iron deficiency anemia in humans or animals and pharmaceutical or food compositions containing them.

The invention describes hydrosoluble iron (III) oxyhydroxide complexes prepared from different sources of iron, amino acids and carboxylic acids. The iron (III) complexes have no undesirable residual taste and can be used as supplementation forms for the prevention or treatment of iron deficiency anemia in humans or animals and pharmaceutical or food compositions containing them.

A metal-EDTA compound/complex for combatting biofilms and/or treating wounds. The compound/complex comprises EDTA and from two to four metal ions. Of those two to four metal ions, at least two are different metal ions selected from Ag, Al, Au, Ba, Bi, Tl, Ce, Co, Cu, Fe, Ga, Ir, Mo, Rh, Ru, Ti, and Zn ions. The metal-EDTA compound/complex may exhibit any one or more of anti-microbial, anti-biofilm and anti-inflammatory activities in use and may increase the susceptibility of a biofilm and the microorganisms within said biofilm to attack by anti-microbial agents, helping to remove and sanitise the biofilm. A composition, wound dressing and medical device comprising the metal-EDTA complex are also provided. Uses of the metal-EDTA compound/complex as a medicament and/or to sanitise and/or substantially remove a biofilm from a substrate are also disclosed.

The present invention relates to a method for preparing a glutamate-based surfactant. More specifically, the present invention provides a method for preparing a glutamate-based surfactant, the method being very economical and being capable of mass production of the glutamate-based surfactant.